Respiro Diagnostics, a United Kingdom-based healthtech company, has secured £1 million in pre-seed funding to advance its breath-based diagnostic platform for detecting lung diseases. The funding round was led by Zinc Venture Capital and SFC Capital, with participation from Amadeus Capital Partners, Conception X Angel Syndicate, KQ Labs, Innovate UK, and strategic angel investors.
The startup is developing non-invasive technology that analyzes exhaled breath to identify lung cancer and other respiratory conditions. Unlike traditional diagnostic methods that often require invasive procedures such as biopsies, Respiro’s approach offers patients a simpler alternative that could enable earlier disease detection.
Supporting Clinical Development
The newly raised capital will be directed toward clinical research and the continued development of the startup’s breath collection device and laboratory platform. This funding represents a significant milestone for the company as it progresses from early-stage concept validation toward clinical implementation.
Alison Quinn, CEO and co-founder of Respiro Diagnostics, outlined the company’s ambition in a statement: “Our vision is simple: that one day, a breath sample is all it takes to know what’s happening in your lungs — early, while there’s still time to act.”
Market Opportunity and Innovation
The global demand for improved diagnostic tools in respiratory healthcare remains substantial. Current diagnostic methods for lung diseases frequently involve time-consuming processes and patient discomfort. Respiro’s breath-based approach addresses these limitations by potentially offering rapid, accessible screening capabilities that could integrate into standard clinical workflows.
The technology sits at the intersection of several high-growth sectors within healthtech, including artificial intelligence-driven diagnostics, point-of-care testing, and non-invasive biomarker analysis. Early-stage companies in these categories have increasingly attracted investor attention as healthcare systems seek to improve diagnostic accuracy while reducing costs and patient burden.
European Healthtech Momentum
The funding round reflects continued investor confidence in European medical diagnostics startups. The UK remains a significant hub for healthtech innovation, with numerous companies developing next-generation diagnostic platforms across various disease areas. The involvement of established venture capital firms like Zinc Venture Capital and Amadeus Capital Partners, alongside government-backed innovation funding through Innovate UK, demonstrates the multi-layered support ecosystem that has developed for promising healthtech ventures.
As respiratory diseases continue to represent a substantial global health burden, companies developing innovative detection methods are positioned at an important intersection of clinical need and technological capability. Respiro’s progress will be closely watched within the broader European startup community as it works to translate its breath analysis platform into clinical applications that could ultimately improve patient outcomes across the continent.